Pro-inflammatory cytokine production downstream of IL-32 and AGE signaling

The term Pro-inflammatory cytokine production downstream of IL-32 and AGE signaling refers to a complex pathological signaling network rather than a single molecular target. This pathway involves the induction of inflammatory mediators such as TNF-alpha, IL-1beta, and IL-6 through the activation of Interleukin-32 (IL-32) and the Receptor for Advanced Glycation End-products (RAGE) (Joosten et al., 2013, Nature Reviews Rheumatology). IL-32 is a potent cytokine that signals through proteinase 3 and integrins to activate NF-kappaB and MAPK pathways, driving the expression of other pro-inflammatory factors (Dahl et al., 2014, Journal of Immunology). Concurrently, the interaction between Advanced Glycation End-products (AGEs) and RAGE triggers intracellular signaling that leads to chronic inflammation and oxidative stress, particularly in the context of diabetes and cardiovascular disease (Ramasamy et al., 2011, Vascular Pharmacology). This combined signaling axis is a major driver of tissue damage in autoimmune diseases like rheumatoid arthritis and metabolic disorders. While the pathway itself is not a discrete therapeutic target, drug development focuses on inhibiting specific components such as RAGE (e.g., Azeliragon) or the resulting cytokines to mitigate disease progression.

Other names

IL-32 signaling pathwayAGE-RAGE signaling axisPro-inflammatory cytokine cascadeIL-32/AGE-induced inflammatory response

Inhibition of ligand-receptor interactions (e.g., RAGE antagonists), neutralization of upstream cytokines (e.g., IL-32 or TNF-alpha antibodies), or blockade of downstream intracellular signaling nodes (e.g., NF-kappaB or MAPK inhibitors) to prevent the synthesis and release of pro-inflammatory mediators.